-
Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)
•
China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in a Phase I clinical study for its ketorolac for IV infusion (NTM-001), a non-opioid analgesic co-developed with US-based Neumentum Inc. Study DetailsThe Phase I study enrolled 16 healthy subjects, who have completed the 96-hour sample…
-
Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has accepted a supplementary Biologic License Application (sBLA) for its HanBeiTai, a biosimilar of Roche’s Avastin (bevacizumab), for review. The application is intended for the treatment of recurrent glioblastoma (GBM). Drug ProfileHanBeiTai was first approved in…
-
CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment
•
China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG: 9960) to advance precision diagnosis and treatment in blood tumors. The partnership aims to enhance educational activities, promote the concept of precision detection and treatment, and improve the accessibility and standardization of genetic testing for…
-
Wanbangde Pharmaceutical to Acquire Consun Pharma Shares in RMB 2.2B Deal
•
China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun Pharmaceutical Group Ltd (HKG: 1681) to acquire 238,056,948 shares at RMB 9.17 (USD 1.36) per share, valuing the transaction at approximately RMB 2.2 billion (USD 325 million). About Consun PharmaceuticalConsun Pharma, listed on the Hong…
-
Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1
•
China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab has demonstrated sustained neutralizing activity against the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 subvariants. Study ResultsLive virus neutralization experiments conducted in the US showed that 14 days after dosing, the total plasma concentration of the combination…
-
CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease
•
China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY Biopharma Co., Ltd, securing global rights to the latter’s tetravalent bispecific antibody (BsAb) targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG2) for intravitreal injection. Financial terms were not disclosed. Agreement DetailsThe deal encompasses…
-
HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration
•
China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging its DNA Encoded Library (DEL) technology to screen compounds for targets identified by LoQus23. The collaboration aims to develop small-molecule drugs targeting DNA mismatch repair (MMR) to slow neurodegeneration in diseases like Huntington’s and myotonic…
-
Roche Diagnostics and Topgen Biopharm Launch Innovation Center in Chongqing
•
Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic partnership on July 24, with the inauguration of the “Roche Diagnostics-Topgen Innovation Center of Excellence” in Chongqing. Center OverviewThe innovation center comprises several key facilities:
